RxDoctor Payments Data

Gregory Owens

Allergy & Immunology · Portland, ORNPI 1043439730

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $933 of the $1,379 with a category attached, or 67.7%. AstraZeneca accounts for 89.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for allergy & immunology clinicians in OR, where the typical reported total is $1,736.

$1,379in general payments, 2019–2025

Across 11 payments — averaging $125.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Astrazeneca UK Limited$141
$233,613in research payments, 2019–2025

Across 141 payments — averaging $1656.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$178K
  • Astrazeneca UK Limited$31K
  • Regeneron$25K

What the payments were for

  • Travel & lodging$93368%
  • Food & beverage$44632%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca9$1,237
Astrazeneca UK Limited2$141

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,379 in reported general payments places this provider in the 45th percentile of 33 allergy & immunology providers in Oregon.

See all allergy & immunology providers in Oregon

Medicare billing

Part B allowed, 2024
$5,039
Medicare patients
37
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab14$59,612
TezspireTezepelumab-Ekko14$57,957
Spiriva RespimatTiotropium Bromide16$11,704
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,985
Albuterol Sulfate HfaAlbuterol Sulfate17$889
Montelukast Sodium52$769
Ipratropium Bromide23$754
Fluticasone Propionate31$728
Azelastine Hcl18$474
Prednisone15$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire$1,237$57,95714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 33 allergy & immunology providers in Oregon.

Other allergy & immunology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →